Fusion Protein Antimicrobial Against Gram-Negative Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial agents, such as antibiotics and endolysins, face challenges in effectively targeting Gram-negative bacteria due to their outer membrane, which shields the bacterial peptidoglycan, and antimicrobial peptides often require high concentrations for efficacy, making them less relevant in vivo.
Innovation Solution
Development of fusion proteins composed of an endolysin or autolysin enzyme with a peptide stretch fused to the N- or C-terminus, specifically designed to degrade the cell wall of Gram-negative bacteria, enhancing their ability to penetrate and target the bacterial membrane.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endolysins are used to target Gram-negative bacteria, then they can degrade the peptidoglycan layer, but the outer membrane prevents access to the peptidoglycan
Solution Approach 1:
The patent applies the intermediary principle by fusing the endolysin enzyme with a peptide that acts as a mediator to facilitate penetration through the outer membrane. The peptide component enables the endolysin to overcome the membrane barrier, while the endolysin component provides the cell wall degradation function. This fusion creates an intermediate structure that bridges the gap between the protective outer membrane and the target peptidoglycan layer.
Solution Approach 2:
The patent merges two distinct functional components into a single fusion protein: the peptide stretch responsible for membrane interaction and penetration, and the endolysin enzyme responsible for peptidoglycan degradation. This combining allows the single molecule to perform both functions sequentially - first penetrating the outer membrane via the peptide portion, then degrading the peptidoglycan via the endolysin portion, thereby resolving the barrier problem.
2Reliability
If antimicrobial peptides are used at high concentrations to achieve efficacy, then bacterial killing is improved, but in vivo relevance decreases due to toxicity and cost
Solution Approach 1:
The patent combines the membrane-targeting peptide with the cell wall-degrading endolysin in a fusion protein. This merging allows the system to achieve effective bacterial killing at lower concentrations because the endolysin provides potent enzymatic activity that complements the peptide's membrane disruption, creating a synergistic effect that reduces the overall quantity of substance needed compared to using high concentrations of peptide alone.
Solution Approach 2:
The fusion protein represents a composite biological material that integrates the properties of both peptides and enzymes. By creating this composite structure, the patent achieves enhanced antibacterial activity that is more potent than either component alone, thereby reducing the concentration required for effective treatment while maintaining in vivo relevance and reducing potential toxicity.
3Reliability
If conventional antibiotics are used, then they are effective against many bacteria, but Gram-negative bacteria show increasing resistance
Solution Approach 1:
The patent replaces the conventional antibiotic mechanism (which relies on binding to specific bacterial targets and is susceptible to resistance development) with an enzymatic mechanism that physically degrades the peptidoglycan cell wall. This substitution of mechanism - using endolysin enzymes that hydrolyze peptidoglycan bonds - creates a novel mode of action that bypasses traditional resistance mechanisms, thereby maintaining reliability against Gram-negative bacteria despite their adaptability and resistance to conventional antibiotics.
Solution Approach 2:
The patent fundamentally changes the parameter of antibacterial mechanism from chemical inhibition (antibiotics binding to targets) to enzymatic degradation (endolysins breaking down cell wall polymers). This parameter change in the mode of action creates a new class of antimicrobial agents that are not subject to the same resistance patterns as conventional antibiotics, thereby addressing the versatility problem of bacterial resistance while maintaining broad effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion proteins demonstrate improved antibacterial activity against Gram-negative bacteria, overcoming the outer membrane barrier and achieving significant bacterial inactivation at lower concentrations compared to unmodified endolysins, thus providing a more effective treatment option for Gram-negative infections.
Implementation Method 1
endolysins are peptidoglycan hydrolases encoded by bacteriophages
Implementation Method 2
amphipathic peptides, which are known to interact with and disrupt bacterial membranes
Data Source
AI summary
The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.